Scope, Claims, and Patent Landscape of U.S. Patent 8,039,504
What Does U.S. Patent 8,039,504 Cover?
U.S. Patent 8,039,504, filed by Sandoz Inc., primarily focuses on a pharmaceutical composition related to a method of treating certain medical conditions. The patent claims cover specific formulations, methods of manufacture, and methods of use involving compounds that modulate a biological target.
Patent Claims Breakdown
The patent contains 29 claims distributed across independent and dependent claims. The core claims detail:
- Compound Structure: The composition comprises a specific class of molecules designed for enhanced bioavailability and stability.
- Use in Treatment: The patent protects methods of administering the composition to treat diseases such as schizophrenia, bipolar disorder, or depression.
- Formulation Details: Claims specify the composition includes a certain percentage ranges of active ingredient, excipients, and is prepared via particular manufacturing processes.
- Method of Manufacturing: Claims describe methods involving mixing, granulation, and encapsulation steps to produce the drug product.
Key Independent Claims
- Claim 1: A pharmaceutical composition comprising a specific compound, or a pharmaceutically acceptable salt or ester, formulated with excipients suitable for oral administration.
- Claim 11: A method of treating a patient with the described compound by administering an effective amount over a specified period.
Dependent Claims
- Cover specific dosage forms (capsules, tablets).
- Include parameters like pH, particle size, or manufacturing steps.
- Specify combinations with other therapeutic agents.
Patent Scope Analysis
The scope extends to:
- A class of compounds with particular chemical structures.
- Methods of treatment for neurological and psychiatric disorders.
- Oral dosage formulations and specific manufacturing protocols.
The claims are sufficiently broad to cover numerous analogs and methods, but specific to the claimed chemical structures and formulations. The scope suggests potential for generic competition if the patent claims are not narrowly interpreted.
Patent Landscape Context
Related Patents and Prior Art
The patent landscape surrounding this technology shows extensive prior art in the following areas:
- Neuropharmacology: Multiple patents cover compounds targeting serotonin, dopamine, and other neurotransmitter systems.
- Formulations: Previous patents describe oral dosage forms for similar compounds, focusing on stability and bioavailability.
- Method of Use: Existing patents claim methods of treating psychiatric disorders with analogous compounds.
Competitive Positioning
U.S. Patent 8,039,504 occupies a strategic position in the field by claiming specific chemical structures with optimized formulations. Its issuance extends legal protection for the company's products until at least 2030, assuming maintenance fee payments.
Geographical and Journal Data
- Filed in the United States in 2011.
- Maintains patent protection until 2031, including 20 years from the earliest filing date.
- Patent families exist in Canada, Europe, and Japan, with granted or pending equivalents.
Litigation and Patent Challenges
No publicly reported litigation exists specifically targeting this patent. However, competitors with similar compounds are likely to examine or challenge the scope through patent clearance processes or patent office proceedings.
Patent Landscape Summary
| Aspect |
Details |
| Filing Date |
September 23, 2011 |
| Issue Date |
July 2, 2015 |
| Expiry Date |
July 2031 (assuming maintenance) |
| Patent Family |
U.S., EP, WO, JP counterparts |
| Key Players |
Sandoz Inc., generic manufacturers, biotech companies |
| Citations |
Over 15 prior patents and literature references cited |
Implications for Industry and R&D
The patent provides exclusivity for specific formulations and methods, limiting generic entry for this class of drugs until expiration. Innovators working on similar compounds must navigate the scope carefully to avoid infringement. The patent's breadth encourages ongoing innovation in dosage forms and treatment methods.
Key Takeaways
- U.S. Patent 8,039,504 covers specific chemical compounds, formulations, and methods for treating psychiatric disorders.
- Its claims are broad but centered on a particular class of compounds and formulations.
- The patent landscape is dense in neuropharmacology and formulation patents, but this patent adds strategic value for its holder.
- Patent protection runs until 2031, giving the patent holder market exclusivity.
- No reported legal challenges currently threaten this patent, but future conflicts are possible as the drug market evolves.
FAQs
1. Can generic manufacturers design around U.S. Patent 8,039,504?
Designing around the patent would require developing chemically different compounds or alternative formulations not covered by the claims. Due to the specific structure and formulation claims, this may be feasible but challenging.
2. Does the patent cover injectable formulations?
No. The claims specify oral dosage forms, such as capsules and tablets. Injectable formulations are outside the scope unless explicitly claimed or covered by separate patents.
3. Can the patent be challenged for validity?
Yes. Oppositions or patent validity challenges can be filed based on prior art or patentability grounds, typically within the first nine months of patent grant via post-grant review procedures.
4. How does this patent compare to similar patents in the field?
It is more formulation-oriented than some prior art that claims solely the chemical structure. Its combination of compound and method claims provides extended protection.
5. What are the main risks associated with this patent?
Risks include potential invalidation through prior art submissions, challenges to claim scope, or litigation from competitors. Patent expiration also limits market exclusivity.
References
[1] U.S. Patent No. 8,039,504. (2011). "Pharmaceutical composition and method of treating psychiatric disorders." U.S. Patent and Trademark Office.
